Tag - SLN


BTIG starts Silence Therapeutics at buy; PT $32

BTIG initiated coverage of Silence Therapeutics (NASDAQ, AIM: SLN) with a “buy” rating and $32 price target. The stock closed at $16.70 on Nov. 17. The company is a development stage therapeutics company based on nearly...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.